Hormonal
Tirzepatide 15 mg once weekly is preferred for individuals with obesity and heart failure with preserved ejection fraction (HFpEF) to improve symptoms and functional capacity, irrespective of glycemic status or weight loss magnitude.
If you have obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide 15 mg once weekly is a preferred treatment to significantly reduce hospitalizations and improve your ability to walk and feel better, even if your blood sugar is normal or you don't lose a lot of weight.
Tirzepatide should be preferred for people with obesity and HFpEF; the CV (MACE) benefit in obesity appears promising but awaits dedicated CVOT data... In the SUMMIT trial, tirzepatide significantly lowered the composite of CV death or HF hospitalization (HR 0.62; 95% CI 0.41–0.95)... It also improved KCCQ-CSS (+ 6.9 points, placebo subtracted) and 6MWD (18.3 m; 95% CI, 9.9–26.7) [11].
Why this rating
Based on the SUMMIT trial, though MACE data is pending, functional outcomes are strong.
Source
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Dario Tuccinardi et al. · Journal of Endocrinological Investigation · 2025
DOI 10.1007/s40618-025-02700-7
More from this paper
- Semaglutide 2.4 mg once weekly significantly reduces major adverse cardiovascular events (MACE) and all-cause mortality in individuals with obesity and established atherosclerotic cardiovascular disease (ASCVD), regardless of diabetes status.Strong
- Semaglutide 2.4 mg once weekly is the preferred first-line anti-obesity medication for individuals with obesity and chronic kidney disease (CKD), including non-diabetic populations, due to significant reductions in renal endpoint progression.Strong
- Tirzepatide 15 mg once weekly is preferred for individuals with obesity and prediabetes when greater weight loss is needed, achieving a 94% risk reduction in diabetes progression over 72 weeks.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →